Traduction de «antibodies on vaccine » (Néerlandais → Français) :

TERMINOLOGIE

vaccin | entstof
vaccin | vaccin

vaccin tegen hondsdolheid
vaccin antirabique

HIB-vaccin
vaccin contre Haemophilus influenzae de type B

hepatitis A+B-vaccin
vaccin contre l'hépatite A et l'hépatite B

hepatitis B-vaccin
vaccin contre l'hépatite B

hepatitis A-vaccin
vaccin contre l'hépatite A

difterie-, tetanus-, kinkhoest-, polio- en heamophilus influenza type b-vaccin
vaccin contre la diphtérie, la coqueluche, le tétanos, la polio et Haemophilus influenzae de type b

vaccin tegen tyfus
vaccin contre la typhoïde

vaccin tegen influenza
vaccin contre le virus de l'influenza

vaccin tegen cholera
vaccin contre le choléra

TRADUCTIONS EN CONTEXTE

-- Reflection paper on the demonstration of a possible impact of maternally derived antibodies on vaccine efficacy in young animals ;
-- Reflection paper on the demonstration of a possible impact of maternally derived antibodies on vaccine efficacy in young animals ;

EFSA - European Food Safety Authority. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of health claims related to conjugated linoleic acid (CLA) isomers and contribution to the maintenance or achievement of a normal body weight (ID 686, 726, 1516, 1518, 2892, 3165), increase in lean body mass (ID 498, 731), increase in insulin sensitivity (ID 1517), protection of DNA, proteins and lipids from oxidative damage (ID 564, 1937), and contribution to immune defences by stimulation of production of protective antibodies in response to vaccination (ID 687, 1519) pursuant to Article 13(1) of Regulation (EC) No 1924/2006.
linoleic acid (CLA) isomers and contribution to the maintenance or achievement of a normal body weight (ID 686, 726, 1516, 1518, 2892, 3165), increase in lean body mass (ID 498, 731), increase in insulin sensitivity (ID 1517), protection of DNA, proteins and lipids from oxidative damage (ID 564, 1937), and contribution to immune defences by stimulation of production of protective antibodies in response to vaccination (ID 687, 1519) pursuant to Article 13(1) of Regulation (EC) No 1924/2006.

2. Mild: IgG subklasse deficiëntie met of zonder IgA deficiëntie, selectieve IgA-deficiëntie, Specific antibody deficiency with normal immunoglobulin concentrations (SAD) (bvb pneumococcenantilichaamdeficientie), Transient hypogammaglobulinemia of infancy (gedaald IgG en IgA): alle vaccins zijn veilig en worden aanbevolen.
2. Modérés: déficit en sous-classe d’IgG avec ou sans déficience en IgA, déficit sélectif en IgA , Specific antibody deficiency with normal immunoglobulin concentrations (SAD) (p. ex. déficience en anticorps antipneumococciques), Transient hypogammaglobulinemia of infancy (IgG et IgA baissées): tous les vaccins sont sans danger et conseillés